Sandwich, UK - 11 December 2025: Particology, a specialist particle science company based at science and business hub Discovery Park, has been selected for an £8.2M Government-funded research consortium to make the manufacture of medicines more efficient and sustainable.
The three-and-a-half year research project is part of Innovate UK’s £54M Sustainable Medicines Manufacturing Innovation Programme and is one of eight “Grand Challenge” projects to develop and demonstrate novel technologies for greener, more efficient medicines manufacturing.
The consortium’s investment has already…
VUGENE is partnering with leading Contract Research Organization (CRO) Inotiv, Inc. (NASDAQ: NOTV) in a new strategic collaboration.
The collaboration is designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. For VUGENE it represents an important entry into the Pharmaceutical Services market.
Through this partnership, Inotiv will integrate VUGENE’s cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division, enabling a more efficient and intelligent analysis of complex…
o2h Discovery is a full-service Contract Research Organisation with R&D sites in Ahmedabad, India, and Cambridge, UK. With over 800 scientists and support staff, we’ve spent two decades partnering with biotech and pharmaceutical companies to advance discovery programmes across the globe. Over these 20 years, we have worked closely with early-stage biotech companies, visionary academics, founders, and innovators determined to push the boundaries of therapeutic science. While a handful of such companies secure significant funding from day one, the reality is that most struggle to…
LONDON, UK - December 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, today announced a further strengthening of its senior leadership with Ian Coyne joining the Managing Partners group. In addition to this strategic leadership expansion, the firm further refined the structure of its Senior Leadership team, with Joe Coulter assuming a new role as Chief Business Officer (CBO) and Charlotte James being promoted to Chief Operating Officer (COO).Ian Coyne, who joined Coulter Partners in 2019, is…
For many in the global life sciences industry, JPM Week at the start of the year in San Francisco is seen a sone of those pivotal weeks that sets the tone for the forthcoming months as investors, companies, advisors and policymakers all converge at scale around a plethora of events and activities.
One Nucleus will be delighted to be supporting our members in their endeavours to connect with their peers and instigate the deal flow that will shape their 2026. Below is a summary of the opportunities for our members:
RESI JPM
12-13 January in person/14, 19 & 20 January virtual partnering
$…
UK has the potential to unlock £8 in socio-economic returns for every £1 spent on preventive healthcare, according to new Deloitte analysis;
Increasing prevention spend from current 6% to 10% could lead to £42 billion of savings to the UK healthcare system in 10 years;
A 7% reduction in preventable deaths could save over 5,400 lives annually, with a societal value of £6 billion.
The UK has the potential to unlock £8[1] in socio-economic returns for every £1 spent on preventive healthcare, according to a new health report by Deloitte.
Analysis in the report: ‘The shift to prevention:…
Cutting-edge product for stem cell research and human embryo modelling
Amsbio reports that its iMatrix-511 recombinant laminin product has been cited in a recent paper** from researchers at the Stanford University School of Medicine, Stanford, CA, USA as a pivotal tool for stem cell culture and blastoid formation.
This groundbreaking study describes how human blastoid models (stem-cell derived blastocyst-like structures) were used to investigate how human-specific LTR5Hs elements regulate early embryonic development. It provides new unique insights into epiblast differentiation and early…
Become a mentor on Beacon’s Patient Group Mentoring Programme and make a real difference to the rare disease community!
Mentees need support across a wide range of areas, from charity management and fundraising to communications, life sciences and more.
You don’t need a background in rare diseases to have something valuable to offer.
As a mentor, you will:
• Be paired with a rare disease patient group leader for a 12-month partnership
• Grow your leadership skills and aid your professional development
• Give back to organisations making a real difference for people living with rare…
Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.
Dr Ibrahim brings over 30 years of experience in the life sciences spanning academia and biotech with a proven track record as a company founder and executive leader. A strategic leader with deep expertise in…
[Letchworth Garden City, December 2025] – DLRC Group has today announced its certification as a B Corporation (or B Corp), joining a growing movement of companies that are reinventing business for the benefit of all people and our shared planet. Verified by B Lab, the not-for-profit behind the B Corp movement, the achievement demonstrates that DLRC Group meets high standards of social and environmental performance, transparency, and accountability alongside a commitment to goals beyond shareholder value.
The news comes as the ongoing climate crisis and widening social inequality continue…